Saturday 17 October 2026
Export JAGX’s income statement to Excel — free account
Jaguar Animal Health, Inc.
JAGX Healthcare Biotechnology
Jaguar Animal Health, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $11.5 million, down 1.52% from fiscal 2024. In the quarter to June 2026, revenue fell 58.9%, EPS grew 95.6%, free cash flow grew 13.8% and total debt fell 83.9%, each against the same quarter a year earlier.
3.53
1.06
−23.09%
Follow JAGX
| Older periods | Sep '25 | Dec '25 | Mar '26 | Jun '26 | |
|---|---|---|---|---|---|
Piotroski F-Score |
+8 more TTM periods Free account |
5 | 3 | 4 | 4 |
| (538.24%) | 729.95% | 671.84% | (1,125.38%) | ||
| (74.66%) | (116.79%) | (112.78%) | (127.14%) | ||
ROIC |
(241.91%) | 0.00% | 0.00% | (28,393.64%) | |
Return on Tangible Assets |
646.03% | 269.95% | 249.97% | 705.52% | |
Average Days of Receivables |
46.58 | 53.84 | 3.46 | 2.60 | |
Free Cash Flow per Share |
(9,191.03) | (5,396.14) | (219.24) | (123.80) | |
Free Cash Flow |
(26.65) | (23.74) | (7.54) | (6.68) | |
Capital Expenditures |
(0.63) | (0.06) | — | — | |
| Other line items | |||||
Cash ROIC |
(171.58%) | (561.70%) | (140.00%) | (50.50%) | |
Accounts Receivable Turnover |
8.39 | 6.88 | 35.43 | 36.74 | |
Accounts Payable Turnover |
0.33 | 0.54 | 0.74 | 0.86 | |
Inventory Turnover |
0.21 | 0.40 | 0.48 | 0.55 | |
Average Days of Payables |
1,446.13 | 840.06 | 409.62 | 355.51 | |
Days of Inventory on Hand |
1,820.38 | 831.65 | 646.13 | 542.64 | |
Tax Rate |
0.00 | 0.00 | 0.00 | 0.00 | |
Research and Development Expense of Revenue |
128.87% | 216.89% | 85.10% | 90.72% | |
Selling, General and Administrative Expense of Revenue |
231.57% | 242.19% | 86.22% | 81.80% | |
Share Based Compensation of Revenue |
9.30% | 7.22% | 2.32% | 2.07% | |
Interest Coverage |
187.56 | (685.19) | (32.00) | (25.95) | |
Operating CF/Net income |
0.65 | 0.44 | 0.15 | 0.13 | |
Depreciation/Fixed assets |
4.66 | 5.09 | 5.51 | 6.59 | |
Capex/Depreciation |
(0.28) | (0.02) | 0.00 | 0.00 | |
Revenue per Share |
4,063.79 | 2,616.14 | 859.56 | 515.09 | |
Operating CF per Share |
(8,973.79) | (5,383.18) | (219.24) | (123.80) | |
Capex per Share |
(217.24) | (12.95) | 0.00 | 0.00 | |
Capex to Sales |
0.05 | 0.01 | 0.00 | 0.00 |
Columns are period end dates · fundamentals updated 2 Oct 2026